Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Taking Advantage of Phage Technologies (TAPT) to Facilitate Phage Therapy While Reducing the Use of Antibiotics in the Management of Cystic Fibrosis (CF)

NCT07280598 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT07280598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07280598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Taking Advantage of Phage Technologies (TAPT) to Facilitate Phage Therapy While Reducing the Use of Antibiotics in the Management of Cystic Fibrosis (CF)
Lead sponsor
University of California, San Diego
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
January 30, 2027
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

achromobacter, cf - cystic fibrosis, e coli infections, klebsiella pneumoniae infection, staphylococcus aureus infection, stenotrophomonas maltophilia infection